+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Hypertensive Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5351783
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Abbott
  • Bayer AG
  • Gilead
  • Lupin Limited
  • Pfizer Inc.
  • Sanofi SA
  • MORE
Anti-Hypertensive Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global anti-hypertensive drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the anti-hypertensive drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Anti-Hypertensive Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:

1) By Therapeutics: Diuretics; Angiotensin Receptor Blockers (ARBs); Angiotensin Converting Enzyme (ACE) Inhibitors; Beta Blockers; Alpha Blockers; Calcium Channel Blockers; Renin Inhibitors; Vasodilators
2) By Disease source: Primary Hypertension; Secondary Hypertension
3) By End users: Hospitals; Clinics; Homecare

Companies Mentioned: Merck & Co.; Astra Zeneca Plc; Daiichi Sankyo Company Limited; Johnson & Johnson Ltd.; Pfizer

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Bayer AG
  • Gilead
  • Lupin Limited
  • Pfizer Inc.
  • Sanofi SA
  • MORE
1. Executive Summary

2. Anti-Hypertensive Drugs Market Characteristics

3. Anti-Hypertensive Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Anti-Hypertensive Drugs

5. Anti-Hypertensive Drugs Market Size And Growth
5.1. Global Anti-Hypertensive Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Anti-Hypertensive Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Anti-Hypertensive Drugs Market Segmentation
6.1. Global Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Diuretics
  • Angiotensin Receptor Blockers (ARBs)
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Beta Blockers
  • Alpha Blockers
  • Calcium Channel Blockers
  • Renin Inhibitors
  • Vasodilators
6.2. Global Anti-Hypertensive Drugs Market, Segmentation By Disease source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Primary Hypertension
  • Secondary Hypertension
6.3. Global Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals
  • Clinics
  • Homecare
7. Anti-Hypertensive Drugs Market Regional And Country Analysis
7.1. Global Anti-Hypertensive Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Anti-Hypertensive Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Anti-Hypertensive Drugs Market
8.1. Asia-Pacific Anti-Hypertensive Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Anti-Hypertensive Drugs Market
9.1. China Anti-Hypertensive Drugs Market Overview
9.2. China Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Anti-Hypertensive Drugs Market
10.1. India Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Anti-Hypertensive Drugs Market
11.1. Japan Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Anti-Hypertensive Drugs Market
12.1. Australia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Anti-Hypertensive Drugs Market
13.1. Indonesia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Anti-Hypertensive Drugs Market
14.1. South Korea Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Anti-Hypertensive Drugs Market
15.1. Western Europe Anti-Hypertensive Drugs Market Overview
15.2. Western Europe Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Anti-Hypertensive Drugs Market
16.1. UK Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Anti-Hypertensive Drugs Market
17.1. Germany Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Anti-Hypertensive Drugs Market
18.1. France Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.2. France Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Anti-Hypertensive Drugs Market
19.1. Eastern Europe Anti-Hypertensive Drugs Market Overview
19.2. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Anti-Hypertensive Drugs Market
20.1. Russia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Anti-Hypertensive Drugs Market
21.1. North America Anti-Hypertensive Drugs Market Overview
21.2. North America Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Anti-Hypertensive Drugs Market
22.1. USA Anti-Hypertensive Drugs Market Overview
22.2. USA Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Anti-Hypertensive Drugs Market
23.1. South America Anti-Hypertensive Drugs Market Overview
23.2. South America Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Anti-Hypertensive Drugs Market
24.1. Brazil Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Anti-Hypertensive Drugs Market
25.1. Middle East Anti-Hypertensive Drugs Market Overview
25.2. Middle East Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Anti-Hypertensive Drugs Market
26.1. Africa Anti-Hypertensive Drugs Market Overview
26.2. Africa Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Anti-Hypertensive Drugs Market, Segmentation By End users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Anti-Hypertensive Drugs Market Competitive Landscape And Company Profiles
27.1. Anti-Hypertensive Drugs Market Competitive Landscape
27.2. Anti-Hypertensive Drugs Market Company Profiles
27.2.1. Merck & Co. Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Astra Zeneca Plc
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Daiichi Sankyo Company Limited
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Johnson & Johnson Ltd.
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Pfizer, Inc.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Anti-Hypertensive Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Anti-Hypertensive Drugs Market

30. Anti-Hypertensive Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Bayer AG
  • Gilead
  • Lupin Limited
  • Pfizer Inc.
  • Sanofi SA
  • MORE
Major players in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca Plc, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer Inc., Novartis AG, Sanofi SA, United Therapeutics, Ranbaxy Laboratories, Bayer AG, Lupin Limited, Boehringer Engelheim GmbH, and Bayer AG.

The global anti-hypertensive drugs market is expected to grow from $24.17 billion in 2020 to $24.37 billion in 2021 at a compound annual growth rate (CAGR) of 0.8%. The slow growth is mainly due to the outbreak of COVID-19 as hypertensive drugs have a negative effect on COVID-19 patients. The market is expected to reach $27.81 billion in 2025 at a CAGR of 3.4%.

The anti-hypertensive drugs market consists of sales of anti-hypertensive drugs and related services. These drugs are re used to prevent heart failure, kidney failure and acute stroke induced by hypertension. Some of the major anti-hypertensive drugs include diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor antagonists.

The market covered in this report is segmented by therapeutics into diuretics, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, beta blockers, alpha blockers, calcium channel blockers, renin inhibitors, vasodilators; by disease source into primary hypertension, secondary hypertension; by end users into hospitals, clinics, homecare.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the anti-hypertensive drugs market. Firstly, most of the people in developing nations neglect their health-check-ups and are not aware about the existing hypertension condition in them until they detect extreme symptoms Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market. For example, BMC Research notes published a research survey (from a developing country) which states that out of the total 112 hypertensive subjects with stroke, only 17% of them were adherent to antihypertensive medications. Lack of awareness and low drug adherence restraint the growth of antihypertensive market.

Of late, there has been rise in use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of a hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When we combine the two drugs with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well.

Sedentary lifestyle is a major driver for the growth of the anti-hypertensive drugs market. Consumption of junk food, lack of proper healthy and balanced diet, lack of proper sleep due to irregular work shifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed of hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market.

The US Food and Drug Administration (FDA) issued a guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. US FDA expects to see a reduction in adverse effects for combinations that include doses below each drugs’ maximum dose compared to single drug regimens at their maximum dose. Earlier physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their programme, current guidelines recommend starting patients on two drugs at less than their full doses. Hence, this guidance would keep a check on the fixed-combination drugs.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Merck & Co. Inc.
  • Astra Zeneca Plc
  • Daiichi Sankyo Company Limited
  • Johnson & Johnson Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • United Therapeutics
  • Ranbaxy Laboratories
  • Bayer AG
  • Lupin Limited
  • Boehringer Engelheim GmbH
  • Bayer AG
  • Sun Pharmaceuticals LLC
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Roche
  • Abbott
  • Gilead
  • Actelion
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll